ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Impact of Aripiprazole (Abilify®) Once Monthly Versus Standard of Care Oral Antipsychotic Medications on Changes in Brain Structure and Metabolism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02237417
Recruitment Status : Recruiting
First Posted : September 11, 2014
Last Update Posted : June 29, 2017
Sponsor:
Collaborator:
Otsuka America Pharmaceutical
Information provided by (Responsible Party):
Deborah Yurgelun-Todd, University of Utah

Brief Summary:

This is a Phase 4, randomized, open-label, parallel group study designed to assess the clinical and biological effects of 12 months of treatment with long acting intramuscular (IM) aripiprazole (Abilify®) as measured by clinical and behavioral measures, and changes on magnetic resonance imaging (MRI) scans in subjects with schizophrenia compared with SOC oral antipsychotic medications and compared with a healthy control group.

It is hypothesized that improved treatment compliance will lead to fewer white matter changes in the brain. Fewer white matter changes will be demonstrated via neuroimaging as increased FA and BPF values in the prefrontal region, and an increase in metabolites in a voxel centered on the anterior cingulate cortex (ACC) as seen with MRS. Therefore, the aim of this study is to examine the structural and metabolic effects of aripiprazole (Abilify®) once monthly in patients with schizophrenia using MRI techniques and to examine these effects in association with cognitive and clinical measures.


Condition or disease Intervention/treatment Phase
Schizophrenia Drug: Standard of Care Oral antipsychotics Drug: IM aripiprazole once monthly Other: No Treatment Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open Label, Parallel Group, Study of the Impact of Aripiprazole (Abilify®) Once Monthly Versus Standard of Care Oral Antipsychotic Medications on Changes in Brain Structure and Metabolism
Study Start Date : September 2014
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : July 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Arm Intervention/treatment
Healthy Control Other: No Treatment
A total of 15 healthy controls will participate in the study and will not receive medication

Active Comparator: Individuals with Schizophrenia (Group A) Drug: Standard of Care Oral antipsychotics
A total of 15 to 20 subjects with schizophrenia will receive SOC oral antipsychotic medications (e.g., aripiprazole (Abilify®), risperidone (Risperdal®), lurasidone HCI (Latuda®), quetiapine fumarate (Seroquel®), olanzapine (Zyprexa®), and ziprasidone HCI(Geodon®)) or once monthly aripiprazole (Abilify®), PO daily, in accordance with their respective product labeling.

Active Comparator: Individuals with Schizophrenia (Group B) Drug: IM aripiprazole once monthly
A total of 30 to 40 subjects with schizophrenia will receive aripiprazole (Abilify®) monthly, at a starting dose of 400 mg IM or an approved dose based on the investigator's judgment and in accordance with product labeling.




Primary Outcome Measures :
  1. Changes in fractional anisotropy (FA) [ Time Frame: 6 and 12 months ]
    To determine if there are differences in prefrontal white matter fractional anisotropy (FA) in subjects with schizophrenia after 6 and 12 months of treatment with aripiprazole (Abilify®) once monthly compared with standard of care (SOC) oral antipsychotic medications (e.g., aripiprazole (Abilify®), risperidone (Risperdal®), lurasidone HCI (Latuda®), quetiapine fumarate (Seroquel®), olanzapine (Zyprexa®), and ziprasidone HCI (Geodon®)).


Secondary Outcome Measures :
  1. Changes in water bound pool fraction (BPF) [ Time Frame: 6 and 12 months ]
    To determine if there are differences in water bound pool fraction (BPF) in prefrontal white matter in subjects with schizophrenia after 6 and 12 months of treatment with aripiprazole (Abilify®) once monthly as compared with SOC oral antipsychotic medications (e.g., aripiprazole (Abilify®), risperidone (Risperdal®), lurasidone HCI (Latuda®), quetiapine fumarate (Seroquel®), olanzapine (Zyprexa®), and ziprasidone HCI (Geodon®)).

  2. Changes in gamma aminobutyric acid (GABA) [ Time Frame: 6 and 12 months ]
    To determine if proton metabolites, specifically gamma aminobutyric acid (GABA), glutamine, and glutamate, are altered in subjects with schizophrenia after 6 and 12 months of treatment with aripiprazole (Abilify®) once monthly compared with SOC oral antipsychotic medications (e.g., aripiprazole (Abilify®), risperidone (Risperdal®), lurasidone HCI (Latuda®), quetiapine fumarate (Seroquel®), olanzapine (Zyprexa®), and ziprasidone HCI (Geodon®)).

  3. Changes in regional white matter and gray matter volume [ Time Frame: 6 and 12 months ]
    To determine if there are differences in regional white matter and gray matter volume in subjects with schizophrenia after 6 and 12 months of treatment with aripiprazole (Abilify®) once monthly compared with SOC oral antipsychotic medications (e.g., aripiprazole (Abilify®), risperidone (Risperdal®), lurasidone HCI (Latuda®), quetiapine fumarate (Seroquel®), olanzapine (Zyprexa®), and ziprasidone HCI (Geodon®)).


Other Outcome Measures:
  1. Association between clinical and neurocognitive variables and FA, BPF, and proton metabolic concentrations [ Time Frame: 12 months ]
    To determine if there is a demonstrated association between clinical and neurocognitive variables and FA, BPF, and proton metabolite concentrations in subjects with schizophrenia receiving SOC oral antipsychotic medications (e.g., aripiprazole (Abilify®), risperidone (Risperdal®), lurasidone HCI (Latuda®), quetiapine fumarate (Seroquel®), olanzapine (Zyprexa®), and ziprasidone HCI(Geodon®)) or once monthly aripiprazole (Abilify®).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria for All Subjects

  • Are able to provide written informed consent.
  • Are male and female subjects 18 to 35 years of age, inclusive, at time of informed consent.

Inclusion Criteria for Subjects with Schizophrenia

  • Have a current diagnosis of schizophrenia as defined by DSM IV-TR criteria and a history of the illness for at least 1 year prior to screening and at least two prior psychotic episodes based on medical records or a qualified and reliable health care provider.
  • Require, in the investigator's judgment, chronic treatment with an antipsychotic medication.
  • Are able to understand the nature of the study and follow protocol requirements, including the prescribed dosage regimens, tablet ingestion, IM depot injection, and discontinuation of prohibited concomitant medications, read and understand the written word in order to complete subject-reported outcomes measures, and be reliably rated on assessment scales.
  • Are male and female subjects who are surgically sterile (i.e., have undergone orchiectomy or hysterectomy, respectively; female subjects who have been postmenopausal for at least 12 consecutive months; or male and female subjects who agree to remain abstinent or to practice double barrier forms of birth control from trial screening through 30 days (for females) and 90 days (for males) from the last dose of IMP for SOC oral antipsychotics and 150 days for females and 180 days for males for aripiprazole depot. If employing birth control, two of the following precautions must be used: vasectomy, tubal ligation, vaginal diaphragm, intrauterine device, birth control pill, birth control implant, birth control depot injections, condom, or sponge with spermicide.

Exclusion Criteria All Subjects

  • Presence of any metal implants, pacemakers, unremovable prosthetic device, or other device or situation that may preclude imaging
  • History of a head injury with loss of consciousness > 5 minutes
  • Has a significant medical condition that would expose the subject to undue risk or interfere with study assessments.

Exclusion Criteria for Subjects with Schizophrenia

  • Has a current DSM-IV-TR diagnosis other than schizophrenia, including schizophreniform disorder, schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnestic or other cognitive disorders. Also excluded are subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.
  • Is considered resistant/refractory to antipsychotic treatment by history (failed two prior antipsychotic medication trials) or response only to clozapine.
  • Has a significant risk of violent behavior or a significant risk of committing suicide based on history or investigator's discretion.
  • Has met DSM-IV-TR criteria for any significant substance use disorder within 3 months prior to screening, excluding caffeine, nicotine, or marijuana.
  • Is known to be allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones, or hypersensitivity to antipsychotic agents, including aripiprazole.
  • Has a history of neuroleptic malignant syndrome or clinically significant tardive dyskinesia at screening per the investigator's discretion.
  • Has a history of seizures or any other medical condition that would expose the subject to undue risk or interfere with study assessments.
  • Is involuntarily incarcerated.
  • Has undergone electroconvulsive therapy in the 2 years prior to enrollment in the study.
  • Has used an investigational agent or has participated in a clinical study with aripiprazole IM depot or any other antipsychotic depot preparation within 30 days of screening.
  • Has clinically significant abnormalities in laboratory test results, vital signs, or ECG results.
  • Requires more than one benzodiazepine beyond screening (e.g., lorazepam and oxazepam).
  • Fails to washout from prohibited concomitant medications, including the use of or CYP3A4 inducers, a second antipsychotic, antidepressants (including monoamine oxidase inhibitors), and mood stabilizers.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02237417


Contacts
Contact: Jennifer DiMuzio, BA 801 857 1471 jennifer.dimuzio@utah.edu
Contact: Jane Sachs, MPH, MBE 801 857 1410 jane.sachs@utah.edu

Locations
United States, Utah
University of Utah Recruiting
Salt Lake City, Utah, United States, 84108
Principal Investigator: Deborah Yurgelun-Todd, PhD         
Sponsors and Collaborators
Deborah Yurgelun-Todd
Otsuka America Pharmaceutical
Investigators
Principal Investigator: Deborah Yurgelun-Todd, PhD University of Utah

Responsible Party: Deborah Yurgelun-Todd, Professor, University of Utah
ClinicalTrials.gov Identifier: NCT02237417     History of Changes
Other Study ID Numbers: COL.AOM.2013.002
First Posted: September 11, 2014    Key Record Dates
Last Update Posted: June 29, 2017
Last Verified: June 2017

Keywords provided by Deborah Yurgelun-Todd, University of Utah:
MRI
Imaging
Antipsychotic

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Antipsychotic Agents
Aripiprazole
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs